Anavex Life Sciences Corp. (0HFR.L)
USD 9.08
(-3.55%)
USD 9.08
(-3.55%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -27.78 Million | -24.23 Million | -30.38 Million | -21.28 Million | -18.52 Million | -12.58 Million |
| Net Income | -47.5 Million | -47.97 Million | -37.9 Million | -26.28 Million | -26.29 Million | -17.45 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 16.37 Million | 18.37 Million | 8.23 Million | 4.87 Million | 6.43 Million | 5.51 Million |
| Change in working capital | 2.5 Million | 5.36 Million | -706.44 Thousand | 116.51 Thousand | 1.3 Million | -646 Thousand |
| Other non-cash items | 845 Thousand | 13.34 Million | 11.76 Million | 6.61 Million | 35.37 Thousand | 5.6 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 29.65 Million | 21.28 Million | 153.24 Million | 28.35 Million | 17.78 Million | 8.07 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 27.87 Million | 20.98 Million | 153.21 Million | 28.75 Million | 17.83 Million | 8.17 Million |
| Other Financing Activities | 1.77 Million | 303.31 Thousand | 23.63 Thousand | -403.76 Thousand | -50 Thousand | -101.13 Thousand |
| Accounts receivables | 484 Thousand | 5.94 Million | -4.28 Million | -2.2 Million | -772.38 Thousand | -231.09 Thousand |
| Accounts payables | 497 Thousand | -915 Thousand | 750.72 Thousand | 465.72 Thousand | 683.79 Thousand | 38.23 Thousand |
| Inventory | -484 Thousand | -5.94 Million | 4.28 Million | 2.2 Million | 772.38 Thousand | - |
| Other working capital | 2 Million | 6.27 Million | -1.45 Million | -349.2 Thousand | 617.81 Thousand | -646 Thousand |
| Cash at beginning of period | 149.15 Million | 152.1 Million | 29.24 Million | 22.18 Million | 22.93 Million | 27.44 Million |
| Cash at end of period | 151.02 Million | 149.15 Million | 152.1 Million | 29.24 Million | 22.18 Million | 22.93 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 1.86 Million | -2.94 Million | 122.85 Million | 7.06 Million | -745 Thousand | -4.5 Million |
| Free Cash Flow | -27.78 Million | -24.23 Million | -30.38 Million | -21.28 Million | -18.52 Million | -12.58 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -12.21 Million | -10.54 Million | -8.62 Million | -10.14 Million | -47.5 Million | -11.27 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.48 Million | 2.65 Million | 2.28 Million | 3.18 Million | 16.37 Million | 3.86 Million |
| Change in working capital | 4.6 Million | -3.76 Million | -982 Thousand | 1.1 Million | 2.5 Million | -239.34 Thousand |
| Other non-cash items | 527 Thousand | 3.45 Million | 3.15 Million | 500.00 | 845 Thousand | 3.42 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 4.55 Million | 7.27 Million | 59 Thousand | 2.05 Million | 29.65 Million | 9 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 4.55 Million | 7.27 Million | 59 Thousand | 1.18 Million | 27.87 Million | 8.53 Million |
| Other Financing Activities | 4.55 Million | 7.27 Million | 59.00 | 868.34 Thousand | 1.77 Million | 468.22 Thousand |
| Accounts receivables | 2.06 Million | -236 Thousand | -840 Thousand | -543.45 Thousand | 484 Thousand | 2.57 Million |
| Accounts payables | -164 Thousand | -566 Thousand | -30 Thousand | 168.93 Thousand | 497 Thousand | -2.12 Million |
| Inventory | - | - | -142 Thousand | 543.45 Thousand | -484 Thousand | -2.57 Million |
| Other working capital | 2.7 Million | -2.96 Million | 30 Thousand | 940.32 Thousand | 2 Million | 1.88 Million |
| Cash at beginning of period | 139.38 Million | 143.76 Million | 151.02 Million | 154.81 Million | 149.15 Million | 153.46 Million |
| Cash at end of period | 138.75 Million | 139.38 Million | 143.76 Million | 151.02 Million | 151.02 Million | 154.81 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -630 Thousand | -4.37 Million | -7.25 Million | -3.79 Million | 1.86 Million | 1.35 Million |
| Free Cash Flow | -5.18 Million | -11.65 Million | -7.31 Million | -5.84 Million | -27.78 Million | -7.65 Million |
IMMNOV
8111
0HYA
3050
GNC
3535